Literature DB >> 18081311

Catalytic properties of ADAM12 and its domain deletion mutants.

Jonas Jacobsen1, Robert Visse, Hans Peter Sørensen, Jan J Enghild, Keith Brew, Ulla M Wewer, Hideaki Nagase.   

Abstract

Human ADAM12 (a disintegrin and metalloproteinase) is a multidomain zinc metalloproteinase expressed at high levels during development and in human tumors. ADAM12 exists as two splice variants: a classical type 1 membrane-anchored form (ADAM12-L) and a secreted splice variant (ADAM12-S) consisting of pro, catalytic, disintegrin, cysteine-rich, and EGF domains. Here we present a novel activity of recombinant ADAM12-S and its domain deletion mutants on S-carboxymethylated transferrin (Cm-Tf). Cleavage of Cm-Tf occurred at multiple sites, and N-terminal sequencing showed that the enzyme exhibits restricted specificity but a consensus sequence could not be defined as its subsite requirements are promiscuous. Kinetic analysis revealed that the noncatalytic C-terminal domains are important regulators of Cm-Tf activity and that ADAM12-PC consisting of the pro domain and catalytic domain is the most active on this substrate. It was also observed that NaCl inhibits ADAM12. Among the tissue inhibitors of metalloproteinases (TIMP) examined, the N-terminal domain of TIMP-3 (N-TIMP-3) inhibits ADAM12-S and ADAM12-PC with low nanomolar Ki(app) values while TIMP-2 inhibits them with a slightly lower affinity (9-44 nM). However, TIMP-1 is a much weaker inhibitor. N-TIMP-3 variants that lack MMP inhibitory activity but retained the ability to inhibit ADAM17/TACE failed to inhibit ADAM12. These results indicate unique enzymatic properties of ADAM12 among the members of the ADAM family of metalloproteinases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18081311     DOI: 10.1021/bi701629c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  24 in total

1.  Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2).

Authors:  Marie Kveiborg; Jonas Jacobsen; Meng-Huee Lee; Hideaki Nagase; Ulla M Wewer; Gillian Murphy
Journal:  Biochem J       Date:  2010-08-15       Impact factor: 3.857

2.  Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function.

Authors:  Charlotte Selvais; Ludovic D'Auria; Donatienne Tyteca; Gwenn Perrot; Pascale Lemoine; Linda Troeberg; Stéphane Dedieu; Agnès Noël; Hideaki Nagase; Patrick Henriet; Pierre J Courtoy; Etienne Marbaix; Hervé Emonard
Journal:  FASEB J       Date:  2011-04-25       Impact factor: 5.191

Review 3.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 4.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 5.  Progress in matrix metalloproteinase research.

Authors:  Gillian Murphy; Hideaki Nagase
Journal:  Mol Aspects Med       Date:  2008-05-24

Review 6.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.

Authors:  Keith Brew; Hideaki Nagase
Journal:  Biochim Biophys Acta       Date:  2010-01-15

7.  Structural characterization of the ectodomain of a disintegrin and metalloproteinase-22 (ADAM22), a neural adhesion receptor instead of metalloproteinase: insights on ADAM function.

Authors:  Heli Liu; Ann H R Shim; Xiaolin He
Journal:  J Biol Chem       Date:  2009-08-18       Impact factor: 5.157

Review 8.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

9.  Evidence for restricted reactivity of ADAMDEC1 with protein substrates and endogenous inhibitors.

Authors:  Jacob Lund; Linda Troeberg; Henrik Kjeldal; Ole H Olsen; Hideaki Nagase; Esben S Sørensen; Henning R Stennicke; Helle H Petersen; Michael T Overgaard
Journal:  J Biol Chem       Date:  2015-01-06       Impact factor: 5.157

Review 10.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.